Eptifibatide how supplied storage and handling

Revision as of 02:11, 6 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Eptifibatide}} {{CMG}}; {{AE}} {{SS}} ==How Supplied Storage And Handling== ===How Supplied=== INTEGRILIN (eptifibatide) injection is supplied as a sterile solu...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Eptifibatide
INTEGRILIN® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eptifibatide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

How Supplied Storage And Handling

How Supplied

INTEGRILIN (eptifibatide) injection is supplied as a sterile solution in 10-mL vials containing 20 mg of INTEGRILIN (NDC 0085-1177-01) and 100-mL vials containing either 75 mg of INTEGRILIN (NDC 0085-1136-01) or 200 mg of INTEGRILIN (NDC 0085-1177-02).

Storage

Vials should be stored refrigerated at 2-8°C (36-46°F). Vials may be transferred to room temperature storage1 for a period not to exceed 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a "DISCARD BY" date (2 months from the transfer date or the labeled expiration date, whichever comes first).

Protect from light until administration.[1]

References

  1. "INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.]". Retrieved 5 February 2014.

Template:WikiDoc Sources